MCID: BRN015
MIFTS: 55

Bronchiolo-Alveolar Adenocarcinoma

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Bronchiolo-Alveolar Adenocarcinoma

MalaCards integrated aliases for Bronchiolo-Alveolar Adenocarcinoma:

Name: Bronchiolo-Alveolar Adenocarcinoma 12 15
Bronchioloalveolar Carcinoma 12 17
Minimally Invasive Lung Adenocarcinoma 12
Adenocarcinoma, Bronchiolo-Alveolar 44
Bronchioloalveolar Adenocarcinoma 71
Bronchioalveolar Lung Carcinoma 12
Carcinoma Bronchioloalveolar 54

Classifications:



External Ids:

Disease Ontology 12 DOID:4926
MeSH 44 D002282
NCIt 50 C2923
SNOMED-CT 67 307595008
UMLS 71 C0007120

Summaries for Bronchiolo-Alveolar Adenocarcinoma

Disease Ontology : 12 A lung adenocarcinoma characterized by a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension.

MalaCards based summary : Bronchiolo-Alveolar Adenocarcinoma, also known as bronchioloalveolar carcinoma, is related to nonmucinous bronchioloalveolar adenocarcinoma and mucinous bronchioloalveolar adenocarcinoma, and has symptoms including fever, dyspnea and hemoptysis. An important gene associated with Bronchiolo-Alveolar Adenocarcinoma is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are CLEC7A (Dectin-1) signaling and MicroRNAs in cancer. The drugs Gefitinib and Mitogens have been mentioned in the context of this disorder. Affiliated tissues include lung, thyroid and lymph node, and related phenotypes are Reduced mammosphere formation and neoplasm

Related Diseases for Bronchiolo-Alveolar Adenocarcinoma

Diseases related to Bronchiolo-Alveolar Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 406)
# Related Disease Score Top Affiliating Genes
1 nonmucinous bronchioloalveolar adenocarcinoma 32.6 NKX2-1 KRT20
2 mucinous bronchioloalveolar adenocarcinoma 32.4 NKX2-1 KRT7 KRT20 CDX2
3 pulmonary adenocarcinoma in situ 30.8 NKX2-1 KRAS EGFR
4 adenocarcinoma 30.8 NKX2-1 MUC4 KRT7 KRAS EGFR CEACAM5
5 papillary adenocarcinoma 30.7 NKX2-1 KRT7 CEACAM5 CDH1
6 adenocarcinoma in situ 30.7 KRT7 KRT20 KRAS CEACAM5 CDX2
7 benign mesothelioma 30.6 NKX2-1 KRT7 KRT20 CEACAM5
8 in situ carcinoma 30.5 MIR17 EGFR CDH1
9 appendix adenocarcinoma 30.5 KRT7 KRT20 KRAS CEACAM5 CDX2
10 goblet cell carcinoid 30.4 KRT20 CDH1
11 peutz-jeghers syndrome 30.4 MUC6 MUC5AC FHIT EGFR
12 lymphangitis 30.4 NKX2-1 CEACAM5
13 cystadenocarcinoma 30.4 MUC5AC KRT7 CEACAM5
14 mucinous cystadenocarcinoma 30.3 KRT7 KRT20 CEACAM5
15 solid adenocarcinoma with mucin production 30.3 NKX2-1 MUC6 MUC5AC KRT7
16 small cell carcinoma 30.2 NKX2-1 KRT7 KRT20 KRAS EGFR CDX2
17 large cell carcinoma 30.2 NKX2-1 KRT7 KRT20 KRAS EGFR CEACAM5
18 mucinous adenocarcinoma 30.1 NKX2-1 MUC5AC KRT7 KRT20 KRAS EGFR
19 malignant pleural mesothelioma 30.1 NKX2-1 MIR17 EGFR
20 small cell cancer of the lung 30.1 NKX2-1 KRT7 KRT20 EGFR CEACAM5
21 lung benign neoplasm 30.0 NKX2-1 KRT7 KRT20 KRAS FHIT EGFR
22 pleural disease 30.0 MIR32 MIR17 EGFR CEACAM5
23 adenoma 29.8 MUC6 MUC5AC KRT7 KRT20 KRAS CDX2
24 mucoepidermoid carcinoma 29.7 NKX2-1 MUC5AC MUC4 KRT7 EGFR CEACAM5
25 lung cancer susceptibility 3 29.7 NKX2-1 MUC5AC MUC4 MIR31 MIR17 KRT7
26 signet ring cell adenocarcinoma 29.5 MUC6 MUC5AC KRT7 KRT20 KRAS CEACAM5
27 leukemia, acute myeloid 29.2 MIR31 MIR30C1 MIR17 KRAS EIF4E EGFR
28 lung cancer 27.4 NKX2-1 MUC5AC MUC4 MIR32 MIR31 MIR30C1
29 mixed mucinous and nonmucinous bronchioloalveolar adenocarcinoma 11.3
30 bladder benign neoplasm 10.4 KRT7 KRT20
31 benign breast adenomyoepithelioma 10.4 KRT7 EGFR
32 nephrogenic adenoma of urinary bladder 10.4 KRT7 KRT20
33 ovary neuroendocrine neoplasm 10.4 KRT7 CDX2
34 atrophic vulva 10.4 KRT7 KRT20
35 ureter small cell carcinoma 10.4 NKX2-1 KRT7
36 intrahepatic biliary papillomatosis 10.4 MUC5AC KRAS
37 cervical mucinous adenocarcinoma 10.4 MUC6 KRT7
38 classic pulmonary blastoma 10.4 NKX2-1 CEACAM5
39 anal canal paget's disease 10.4 KRT7 CDX2
40 larynx sarcoma 10.4 NKX2-1 CEACAM5
41 gallbladder signet ring cell adenocarcinoma 10.4 KRT7 CDH1
42 gastric signet ring cell adenocarcinoma 10.4 KRT7 CDX2
43 leukoplakia of penis 10.4 KRT7 CEACAM5
44 acneiform dermatitis 10.4 KRAS EGFR
45 adenosquamous colon carcinoma 10.4 KRT7 CDX2
46 signet ring basal cell carcinoma 10.4 KRAS CEACAM5
47 bartholin's gland disease 10.4 KRT7 CDX2
48 esophagus verrucous carcinoma 10.4 EGFR CDH1
49 adenosquamous lung carcinoma 10.4 KRAS EGFR
50 bartholin's gland carcinoma 10.4 KRT7 CDX2

Graphical network of the top 20 diseases related to Bronchiolo-Alveolar Adenocarcinoma:



Diseases related to Bronchiolo-Alveolar Adenocarcinoma

Symptoms & Phenotypes for Bronchiolo-Alveolar Adenocarcinoma

UMLS symptoms related to Bronchiolo-Alveolar Adenocarcinoma:


fever, dyspnea, hemoptysis, coughing

GenomeRNAi Phenotypes related to Bronchiolo-Alveolar Adenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CDH1 EGFR EIF4E HYAL2 KRAS KRT7

MGI Mouse Phenotypes related to Bronchiolo-Alveolar Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.23 CDH1 CDX2 EGFR EIF4E FHIT KRAS

Drugs & Therapeutics for Bronchiolo-Alveolar Adenocarcinoma

Drugs for Bronchiolo-Alveolar Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
2 Mitogens Phase 3
3
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
4
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
5
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
6
nivolumab Approved Phase 2 946414-94-4
7
Ipilimumab Approved Phase 2 477202-00-9
8
Lenograstim Approved, Investigational Phase 2 135968-09-1
9
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
10
Metformin Approved Phase 2 657-24-9 14219 4091
11
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 446556 60843
12
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
13
Bevacizumab Approved, Investigational Phase 2 216974-75-3
14
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
15
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
16
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
17
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
18
Glutamic acid Approved, Nutraceutical Phase 2 56-86-0 33032
19
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
20
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
21
Veliparib Investigational Phase 1, Phase 2 912444-00-9 11960529
22
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
23 Immunoglobulins Phase 2
24 Antibodies Phase 2
25 Antibodies, Monoclonal Phase 2
26 Immunoglobulin G Phase 2
27 Keratolytic Agents Phase 2
28 Adjuvants, Immunologic Phase 2
29 Dermatologic Agents Phase 2
30 Podophyllotoxin Phase 2 518-28-5
31 Endothelial Growth Factors Phase 2
32 Poly(ADP-ribose) Polymerase Inhibitors Phase 1, Phase 2
33 Hypoglycemic Agents Phase 2
34 Folic Acid Antagonists Phase 2
35 Vitamin B Complex Phase 2
36 Folate Phase 2
37 Protein Kinase Inhibitors Phase 2
38 Vitamin B9 Phase 2
39 Angiogenesis Inhibitors Phase 2
40 Antineoplastic Agents, Immunological Phase 2
41 Albumin-Bound Paclitaxel Phase 2
42 Antimitotic Agents Phase 2
43 Tubulin Modulators Phase 2
44 Vaccines Phase 2
45
Etoposide Approved Phase 1 33419-42-0 36462
46 Soy Bean Phase 1
47 Immunologic Factors Phase 1
48 Immunoglobulins, Intravenous Phase 1
49 Etoposide phosphate Phase 1

Interventional clinical trials:

(show all 31)
# Name Status NCT ID Phase Drugs
1 Randomized Phase II/III Trial of Paclitaxel Plus Carboplatin With or Without Bevacizumab (NSC #704865) in Patients With Advanced Nonsquamous NSCLC Completed NCT00021060 Phase 2, Phase 3 paclitaxel;carboplatin
2 A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With Consolidation Docetaxel Followed by Maintenance Therapy With ZD1839 (NSC-715055) or Placebo in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
3 A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer Completed NCT00049543 Phase 3 gefitinib
4 A PHASE III STUDY OF ADJUVANT CHEMOTHERAPY AFTER RESECTION FOR PATIENTS WITH T2N0 STAGE I NON-SMALL CELL CARCINOMA OF THE LUNG Completed NCT00002852 Phase 3 paclitaxel;carboplatin
5 Prospective Evaluation of Small Molecule EGFR-1 Tyrosine Kinase Inhibition as a First-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harbouring a Mutant EGFR Gene Unknown status NCT00339586 Phase 2 Erlotinib
6 A Randomized Phase II Study of Schedule-Modulated Concomitant Pemetrexed (Alimta) and Erlotinib (Tarceva) vs Single Agent Pemetrexed (Alimta®) in Patients With Progressive or Recurrent Non-small Cell Lung Cancer (NSCLC) Completed NCT00950365 Phase 2 Erlotinib Hydrochloride;Pemetrexed Disodium
7 Phase II Trial of Chronic Oral ZD1839 (Iressa®) (NSC-715055) in Both Previously-Untreated and Previously-Treated Patients With Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) Completed NCT00029003 Phase 2 gefitinib
8 A Phase II Trial of the Combination of OSI-774 (ERLOTINIB; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features (ADENOBAC) Completed NCT00436332 Phase 2 erlotinib hydrochloride
9 Effect of an Early Therapeutic Permutation on the Tumoral Control of Patients Receiving in First Line a Specific Inhibitor of Tyrosin Kinase of EGFR (Erlotinib) or a Taxan-based Chemotherapy for the Treatment of Not Resecable Adenocarcinoma With Bronchiolo-alveolar. Completed NCT00384826 Phase 2 erlotinib;paclitaxel + carboplatine
10 Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy Completed NCT01294306 Phase 2 Akt Inhibitor MK2206;Erlotinib Hydrochloride
11 A Phase II Trial of Combination Carboplatin, Paclitaxel, Cetuximab and Bevacizumab (NSC-704865) Followed By Cetuximab and Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00368992 Phase 2 paclitaxel
12 A Phase II Randomized Study of OSI-774 (Erlotinib) (NSC #718781) With or Without Carboplatin/Paclitaxel in Patients With Previously Untreated Adenocarcinoma of the Lung Who Never Smoked or Were Former Light Smokers Completed NCT00126581 Phase 2 Carboplatin;Erlotinib;Erlotinib Hydrochloride;Paclitaxel
13 Phase II Study of Bortezomib (PS-341) for Patients With Advanced Bronchiolo-Alveolar Carcinoma (BAC) or Adenocarcinoma With BAC Features Completed NCT00118144 Phase 2 bortezomib
14 ZD1839 (NSC #715055, IND #61187) With Induction Paclitaxel And Carboplatin Followed By Either Radiation Or Concomitant Radiation With Weekly Paclitaxel And Carboplatin In Stage III Non-Small Cell Lung Cancer, A Phase II Study Completed NCT00040794 Phase 2 paclitaxel;carboplatin;gefitinib
15 Phase II Study of Sequential Dose-Dense Chemotherapy and Dose-Intense Erlotinib for the Initial Treatment of Advanced Non-Small Cell Lung Cancer Completed NCT01557959 Phase 2 cisplatin;erlotinib hydrochloride;docetaxel
16 Phase II Trial of Paclitaxel by 96-Hour Infusion in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) Completed NCT00002969 Phase 2 paclitaxel
17 Phase II Randomized Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa, or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR Recruiting NCT03110978 Phase 2
18 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
19 A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage III Non-small Cell Lung Cancer Active, not recruiting NCT00334815 Phase 2 Cisplatin;Docetaxel;Etoposide
20 A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811) Active, not recruiting NCT01386385 Phase 1, Phase 2 Carboplatin;Paclitaxel;Veliparib
21 Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC Active, not recruiting NCT02186847 Phase 2 Carboplatin;Metformin;Paclitaxel
22 A Multicenter, Open-Label, Phase 2 Study of VELCADE (Bortezomib) for Injection in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma and Adenocarcinoma With Bronchioloalveolar Features Terminated NCT00117351 Phase 2 VELCADE
23 A Phase II Randomized Trial of Paclitaxel, Carboplatin, Bevacizumab With or Without IMC-A12 in Patients With Advanced Non-squamous, Non-small Cell Lung Cancer Terminated NCT00955305 Phase 2 Carboplatin;Paclitaxel
24 Phase II Trial of CG8123, an Autologous Cancer Vaccine (GVAX), in Patients With Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) Terminated NCT00074295 Phase 2
25 A Phase 2 Multicenter Trial Comparing Two Schedules of GW572016 as First or Second Line Monotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer With Either Bronchioloalveolar Carcinoma or No Smoking History Terminated NCT00073008 Phase 2 GW572016 (lapatinib)
26 Phase II Trial of Pemetrexed in Patients With Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) Terminated NCT00265785 Phase 2 pemetrexed
27 Phase I Study of Thoracic Radiotherapy and Concurrent Chemotherapy With Soy Isoflavones in Stage III NSCLC (Non-Small Cell Lung Cancer) Patients Completed NCT01958372 Phase 1 cisplatin;etoposide;pemetrexed disodium
28 A Phase I Study Of OSI-774 (NSC #718781)-Based Multimodality Therapy For Inoperable Stage III Non Small Cell Lung Cancer Terminated NCT00042835 Phase 1 cisplatin;etoposide;erlotinib hydrochloride;docetaxel;paclitaxel;carboplatin
29 A Safety and Feasibility Study of Bevacizumab With Paclitaxel, Carboplatin and Chest Radiotherapy in Patients With Locally Advanced Non-Small Lung Cancer Terminated NCT00369551 Phase 1 paclitaxel;carboplatin
30 Prospective Cohort Study of Telomere Biology Among Patients With Early Adenocarcinoma of the Lung Unknown status NCT02239432
31 The PIONEER Initiative: Precision Insights On N-of-1 Effectiveness Research. Tissue Ownership by the Individual With the Return of Actionable Information to the Individual Patient and Physician (Precision Oncology) Recruiting NCT03896958

Search NIH Clinical Center for Bronchiolo-Alveolar Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma, bronchiolo-alveolar

Genetic Tests for Bronchiolo-Alveolar Adenocarcinoma

Anatomical Context for Bronchiolo-Alveolar Adenocarcinoma

MalaCards organs/tissues related to Bronchiolo-Alveolar Adenocarcinoma:

40
Lung, Thyroid, Lymph Node, Endothelial, Pituitary, Whole Blood, Spleen

Publications for Bronchiolo-Alveolar Adenocarcinoma

Articles related to Bronchiolo-Alveolar Adenocarcinoma:

(show top 50) (show all 991)
# Title Authors PMID Year
1
Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component. 54 61
20439191 2010
2
Promoter methylation of glutathione S-transferase pi1 and multidrug resistance gene 1 in bronchioloalveolar carcinoma and its correlation with DNA methyltransferase 1 expression. 54 61
20120028 2010
3
Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? 61 54
20073607 2010
4
Promoter methylation of glutathione S-transferase pi1 and multidrug resistance gene 1 in bronchioloalveolar carcinoma and its correlation with DNA methyltransferase 1 expression. 61 54
19484794 2009
5
Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. 54 61
19260752 2009
6
Bronchioloalveolar carcinoma presenting as chronic progressive pulmonary infiltrates in a woman with HIV: a diagnosis worth making. 54 61
18978572 2008
7
Long-lasting complete remission with tyrosine kinase inhibitor in bronchioloalveolar carcinoma with a so far unknown EGFR mutation. 54 61
18379371 2008
8
Epidermal growth factor receptor signaling in adenocarcinomas with bronchioloalveolar components. 54 61
18154814 2008
9
Microsatellite and EGFR, HER2 and K-RAS analyses in sclerosing hemangioma of the lung. 54 61
17895751 2007
10
MUC-1 (CA 15-3 antigen) as a highly reliable predictor of response to EGFR inhibitors in patients with bronchioloalveolar carcinoma: an experience on 26 patients. 54 61
18161663 2007
11
[Value of thyroid transcription factor-1 in identification of the prognosis of bronchioloalveolar carcinoma]. 54 61
18036300 2007
12
Epidermal growth factor receptor gene mutations in atypical adenomatous hyperplasias of the lung. 54 61
17618248 2007
13
Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. 61 54
17591931 2007
14
[Comparison of the characteristics in recurrence and metastasis between bronchioloalveolar carcinoma and other lung adenocarcinomas]. 54 61
17626761 2007
15
Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. 54 61
17580276 2007
16
Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma. 61 54
17427221 2007
17
Short-term gefitinib treatment brought about a long-term regression of bronchioloalveolar carcinoma without EGFR gene alterations: a case report. 54 61
18196873 2007
18
Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma. 61 54
16353158 2006
19
A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma. 61 54
16449241 2006
20
Bronchioloalveolar carcinoma of mixed mucinous and nonmucinous type: immunohistochemical studies and mutation analysis of the p53 gene. 61 54
16959434 2006
21
Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation. 61 54
16009451 2005
22
Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung. 54 61
16189154 2005
23
Gefitinib inhibits MUC5AC synthesis in mucin-secreting non-small cell lung cancer cells. 61 54
16009452 2005
24
Loss of expression of E-cadherin and beta-catenin is associated with progression of pulmonary adenocarcinoma. 61 54
15660698 2005
25
Cadherin superfamily of adhesion molecules in primary lung cancer. 54 61
15627055 2004
26
Usefulness of Cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma. 54 61
15362373 2004
27
Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition. 61 54
15217959 2004
28
Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung. 54 61
15151204 2004
29
Differential expression of cytokeratins 7 and 20 and thyroid transcription factor-1 in bronchioloalveolar carcinoma: an immunohistochemical study in fine-needle aspiration biopsy specimens. 61 54
15023039 2004
30
Prognostic significance of thyroid transcription factor-1 expression in both early-stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. 61 54
14745718 2004
31
Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma. 61 54
14596689 2003
32
Prognostic significance of E-cadherin and beta-catenin in resected stage I non-small cell lung cancer. 61 54
12965318 2003
33
Hyaluronidase 2 negatively regulates RON receptor tyrosine kinase and mediates transformation of epithelial cells by jaagsiekte sheep retrovirus. 61 54
12676986 2003
34
Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. 54 61
12374671 2002
35
Expression of cytokeratin 20 in mucinous bronchioloalveolar carcinoma. 54 61
12378517 2002
36
Expression of thyroid transcription factor-1, cytokeratin 7, and cytokeratin 20 in bronchioloalveolar carcinomas: an immunohistochemical evaluation of 67 cases. 61 54
12011259 2002
37
Mucinous bronchioloalveolar carcinomas display a specific pattern of mucin gene expression among primary lung adenocarcinomas. 61 54
11274635 2001
38
Basement membrane patterns, gelatinase A and tissue inhibitor of metalloproteinase-2 expressions, and stromal fibrosis during the development of peripheral lung adenocarcinoma. 61 54
10088553 1999
39
Expression of E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin in bronchioloalveolar carcinoma and conventional pulmonary adenocarcinoma: an immunohistochemical study. 54 61
9831199 1998
40
FHIT and p53 gene abnormalities in bronchioloalveolar carcinomas. Correlations with clinicopathological data and K-ras mutations. 54 61
9614374 1998
41
Novel PD-L1 mAb HC16 reveals upregulation of PD-L1 in BAC subtype. 61
33112410 2020
42
Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study. 61
32395526 2020
43
Typical presentation of pulmonary lepidic adenocarcinoma: a rare case report. 61
32550974 2020
44
Focal organizing pneumonia in patients: differentiation from solitary bronchioloalveolar carcinoma using dual-energy spectral computed tomography. 61
32774750 2020
45
EGFR and HER3 signaling blockade in invasive mucinous lung adenocarcinoma harboring an NRG1 fusion. 61
30268483 2018
46
Impact of viral presence in tumor on gene expression in non-small cell lung cancer. 61
30134863 2018
47
Combination of positron emission tomography/computed tomography and chest thin-layer high-resolution computed tomography for evaluation of pulmonary nodules: Correlation with imaging features, maximum standardized uptake value, and pathology. 61
30075545 2018
48
Favorable response to pemetrexed, cisplatin and bevacizumab in invasive mucinous adenocarcinoma: A case report and literature review. 61
30101020 2018
49
Cheerios Floating on Lung Computed Tomography Scan Revealing Cholangiocarcinoma of the Lungs. 61
29922538 2018
50
Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. 61
28801183 2018

Variations for Bronchiolo-Alveolar Adenocarcinoma

Cosmic variations for Bronchiolo-Alveolar Adenocarcinoma:

9 (show top 50) (show all 35906)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88263727 ZRSR2 lung,NS,carcinoma,adenocarcinoma c.937+1G>T p.? 23:15820317-15820317 9
2 COSM95442728 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 9
3 COSM85262562 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.622C>T p.R208C 3:50342996-50342996 9
4 COSM85263435 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 9
5 COSM95441934 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.599+122C>T p.? 3:50342996-50342996 9
6 COSM143112283 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 9
7 COSM101592316 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 9
8 COSM101606460 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 9
9 COSM101614868 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.369G>C p.E123D 13:19993441-19993441 9
10 COSM101585076 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 9
11 COSM101614672 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 9
12 COSM143112460 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.369G>C p.E123D 13:19993441-19993441 9
13 COSM143103178 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 9
14 COSM101592471 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.369G>C p.E123D 13:19993441-19993441 9
15 COSM102032968 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-7406A>C p.? 16:72958371-72958371 9
16 COSM102040512 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1439C>A p.S480* 16:72798501-72798501 9
17 COSM102043690 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8060C>T p.S2687L 16:72787474-72787474 9
18 COSM87286137 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3340C>G p.R1114G 16:72889839-72889839 9
19 COSM102031099 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7886C>A p.A2629D 16:72787648-72787648 9
20 COSM149303773 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3340C>G p.R1114G 16:72889839-72889839 9
21 COSM149318853 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.331G>A p.E111K 16:72959815-72959815 9
22 COSM149318882 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2680G>T p.D894Y 16:72957466-72957466 9
23 COSM149268808 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.256G>T p.A86S 16:72959890-72959890 9
24 COSM102042371 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-6501G>T p.? 16:72957466-72957466 9
25 COSM102037223 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-7773G>T p.? 16:72958738-72958738 9
26 COSM149260552 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10961C>T p.S3654L 16:72787315-72787315 9
27 COSM87273791 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2755G>T p.G919C 16:72950930-72950930 9
28 COSM87274581 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7769C>G p.S2590C 16:72794913-72794913 9
29 COSM87284855 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.4834G>C p.E1612Q 16:72797848-72797848 9
30 COSM149303017 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2701G>A p.A901T 16:72957445-72957445 9
31 COSM102022101 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6240C>G p.F2080L 16:72793700-72793700 9
32 COSM102032971 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-7046G>T p.? 16:72958011-72958011 9
33 COSM87287980 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2767G>T p.V923L 16:72950918-72950918 9
34 COSM149309579 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2767G>T p.V923L 16:72950918-72950918 9
35 COSM102028052 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2928G>C p.Q976H 16:72797012-72797012 9
36 COSM149263533 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1910G>A p.G637E 16:72958236-72958236 9
37 COSM149322707 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10802C>T p.S3601L 16:72787474-72787474 9
38 COSM87279299 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6293C>T p.S2098L 16:72796389-72796389 9
39 COSM149327483 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1582C>T p.Q528* 16:72958564-72958564 9
40 COSM87274095 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.628G>T p.G210C 16:72959518-72959518 9
41 COSM102037726 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.689G>T p.C230F 16:72889748-72889748 9
42 COSM102022617 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.13G>T p.G5C 16:72950930-72950930 9
43 COSM149265687 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8982C>G p.F2994L 16:72793700-72793700 9
44 COSM87281915 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6289T>G p.F2097V 16:72796393-72796393 9
45 COSM149269636 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7769C>G p.S2590C 16:72794913-72794913 9
46 COSM102047871 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3243C>G p.I1081M 16:72796697-72796697 9
47 COSM149263422 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.941G>A p.R314Q 16:72959205-72959205 9
48 COSM102041859 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1021C>T p.P341S 16:72811678-72811678 9
49 COSM87272331 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.941G>A p.R314Q 16:72959205-72959205 9
50 COSM149290601 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10628C>A p.A3543D 16:72787648-72787648 9

Expression for Bronchiolo-Alveolar Adenocarcinoma

Search GEO for disease gene expression data for Bronchiolo-Alveolar Adenocarcinoma.

Pathways for Bronchiolo-Alveolar Adenocarcinoma

Pathways related to Bronchiolo-Alveolar Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.97 MUC6 MUC5AC MUC4 KRAS
2 11.59 MIR32 MIR31 MIR30C1 MIR17 KRAS EGFR
3 11.2 KRAS EGFR CDH1
4 10.91 NKX2-1 CDX2 CDH1

GO Terms for Bronchiolo-Alveolar Adenocarcinoma

Cellular components related to Bronchiolo-Alveolar Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 MUC6 MUC5AC MUC4 MIR31 MIR30C1 MIR17
2 extracellular matrix GO:0031012 9.26 MUC6 MUC5AC MUC4 LOX

Biological processes related to Bronchiolo-Alveolar Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.72 MIR32 MIR31 MIR30C1 MIR17 MIR146B
2 maintenance of gastrointestinal epithelium GO:0030277 9.37 MUC6 MUC4
3 O-glycan processing GO:0016266 9.33 MUC6 MUC5AC MUC4
4 negative regulation of fibroblast migration GO:0010764 9.26 MIR146B HYAL2
5 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.26 MUC6 MUC5AC MUC4 KRAS
6 lung development GO:0030324 8.92 NKX2-1 LOX EIF4E EGFR

Molecular functions related to Bronchiolo-Alveolar Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.02 MIR32 MIR31 MIR30C1 MIR17 MIR146B

Sources for Bronchiolo-Alveolar Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....